Marie Osdoit
A5029749345- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- Cancer Genomics and Diagnostics
- Cancer Risks and Factors
- HER2/EGFR in Cancer Research
- Radiomics and Machine Learning in Medical Imaging
- Cancer Treatment and Pharmacology
- Global Cancer Incidence and Screening
- Cardiac, Anesthesia and Surgical Outcomes
- Meta-analysis and systematic reviews
- Endometrial and Cervical Cancer Treatments
- Medical Imaging Techniques and Applications
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Surgical Treatments
- Biomedical Text Mining and Ontologies
- Spinal Hematomas and Complications
- Advanced Radiotherapy Techniques
- Cervical Cancer and HPV Research
- Cervical and Thoracic Myelopathy
- Surgical Simulation and Training
- Anatomy and Medical Technology
- Ovarian cancer diagnosis and treatment
- Multiple and Secondary Primary Cancers
- Advanced Breast Cancer Therapies
Institut Curie
2019-2025
University of California, San Francisco
2021-2022
Université Paris Sciences et Lettres
2021
City College of San Francisco
2020
Hôpital Européen Georges-Pompidou
2019
BackgroundPrevious studies have independently validated the prognostic relevance of residual cancer burden (RCB) after neoadjuvant chemotherapy. We used results from several independent cohorts in a pooled patient-level analysis to evaluate relationship RCB with long-term prognosis across different phenotypic subtypes breast cancer, assess generalisability broad range practice settings.MethodsIn this analysis, 12 institutes and trials Europe USA were identified by personal communications...
Introduction The Residual Cancer Burden (RCB) quantifies residual disease after neoadjuvant chemotherapy (NAC). Its predictive value has not been validated on large cohorts with long-term follow up. objective of this work is to independently evaluate the prognostic RCB index depending BC subtypes (Luminal, HER2-positive and triple negative (TNBCs)). Methods We retrospectively evaluated surgical specimens from a cohort T1-T3NxM0 patients treated NAC between 2002 2012. analyzed association...
Abstract Residual Cancer Burden (RCB) after neoadjuvant chemotherapy (NAC) is validated to predict event-free survival (EFS) in breast cancer but has not been studied for invasive lobular carcinoma (ILC). We patient-level data from a pooled cohort across 12 institutions. Associations between RCB index, class, and EFS were assessed ILC non-ILC with mixed effect Cox models multivariable analyses. Recursive partitioning was used an exploratory model stratify prognosis by components. Of 5106...
Abstract Background: Recent studies have demonstrated independent validation of the prognostic relevance residual cancer burden (RCB) after neoadjuvant chemotherapy. However, a pooled subject-level analysis multiple cohorts is needed to determine estimates long-term prognosis for each class RCB in phenotypic subtype breast (BC) better inform on patient outcomes. Also, allows more detailed analyses generalizability meaning assessments broader experience practice settings. Method:...
Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer strongly correlates with overall survival and has become the standard end point trials. However, there is controversy regarding whether definition of pCR should exclude or permit presence residual ductal carcinoma situ (DCIS).To examine association DCIS surgical specimens for points to inform standards assessment pathologic response.The study team analyzed NAC 3-year event-free (EFS), distant...
To apply text mining (TM) technology on electronic medical records (EMRs) of patients with breast cancer (BC) to retrieve the occurrence a pregnancy after BC diagnosis and compare its performance manual curation.The training cohort (Cohort A) comprised 344 age ≤ 40 years old treated at Institut Curie between 2005 2007. Manual curation consisted in manually reviewing each EMR pregnancies. TM first applying keyword filter ("accouch*" or "enceinte," French terms for "deliver*" "pregnant,"...
ABSTRACT Introduction The Residual Cancer Burden (RCB) quantifies residual disease after neoadjuvant chemotherapy (NAC). Its predictive value has not been validated on large cohorts with long-term follow up. objective of this work is to independently evaluate the prognostic RCB index depending BC subtypes (Luminal, HER2 -positive and triple negative (TNBCs)). Methods We retrospectively evaluated surgical specimens from a cohort T1-T3NxM0 patients treated NAC between 2002 2012. analyzed...
Although identified to be at a higher risk of relapse, no consensus exists on the treatment breast cancer (BC) patients with pathological complete response after neoadjuvant chemotherapy (NAC). The benefit adjuvant (ADJ) in this context has scarcely been studied. We evaluated administrating real life cohort BC invasive residual disease NAC. 1199 female T1-3NxM0 tumors receiving NAC Institut Curie from 2002 2012 were included analysis. 1061 had treated by only, whereas 138 received additional...
Survival disparities persist in ovarian cancer and may be linked to the environments which patients live. The main objective of this study was analyze global impact area residence on overall survival. data were obtained from Surveillance, Epidemiology End Results (SEER) database. We included all with epithelial cancers diagnosed between 2010 2016. areas analyzed by hierarchical clustering principal components group similar counties. A multivariable Cox proportional hazards model then fitted...
The treatment of breast cancer, the leading cause cancer and mortality among women worldwide, is mainly on basis surgery. In this study, we describe use a medical image visualization tool virtual reality (VR), entitled DIVA, in context tumor localization surgeons. aim study was to evaluate speed accuracy surgeons using DIVA for analysis magnetic resonance (MRI) scans relative standard slice-based tools.
Abstract Background: Pathologic complete response (pCR) after neoadjuvant chemotherapy (NAC) in patients with breast cancer is associated improved survival. Further assessment of the extent residual disease, using pathological anatomic American Joint Committee on Cancer staging method (ypStage) or Residual Burden (RCB) method, have been shown to add prognostic information for disease. Neo-Bioscore, an alternate system classify NAC, includes clinical stage at diagnosis and biology defines...
Abstract Background: Patients who achieve a pathological complete response (pCR- defined as no invasive cancer) after neoadjuvant chemotherapy (NAC) for breast cancer (BC) have improved outcomes, but there is still controversy about the significance of residual ductal carcinoma in situ (DCIS) on local recurrence rate (LRR). The I-SPY 2 TRIAL an adaptive platform trial evaluating novel experimental regimens comparison to standard women with high-risk cancer. purpose this study determine if...
Abstract Background: Achieving a pathologic complete response (pCR) has been shown on the patient level to predict excellent long-term event-free survival outcomes. Residual cancer burden (RCB) quantifies extent of residual disease for patients who did not achieve pCR. We have previously observed in I-SPY 2 TRIAL that while metastatic events outside central nervous system (CNS) were dramatically reduced setting pCR, incidence CNS metastasis remained similar across RCB classes, raising...